Key Takeaways
- Abbott delivered Q1 earnings per share of $1.15, aligning with analyst projections of $1.14–$1.15
- Quarterly revenue reached $11.16B, surpassing the $11B Wall Street forecast
- The cancer diagnostics division, strengthened by acquiring Exact Sciences, contributed to strong performance
- Medical device business, the company’s biggest revenue generator, maintained solid momentum
- Second-quarter EPS forecast of $1.25–$1.31 fell modestly short of the $1.32 analyst target
Abbott Laboratories unveiled its first-quarter financial performance on April 16, surpassing analyst revenue projections with a notable contribution from its recently integrated cancer diagnostics operation.
The healthcare giant delivered adjusted earnings per share of $1.15 for the period. This figure aligned precisely with one analyst forecast of $1.15 and exceeded an alternative consensus projection of $1.14 by one cent, varying by data provider.
Quarterly revenue totaled $11.16 billion, comfortably beating the $11 billion Wall Street consensus.
Shares settled at $101.56 prior to the earnings announcement. ABT has declined 16.59% during the preceding three-month period and has fallen 22.46% year-over-year.
The Exact Sciences transaction significantly influenced this quarter’s financial results. Abbott finalized an agreement in November to acquire the cancer diagnostics specialist for $105 per share, representing a total transaction value approaching $23 billion. The acquisition completed in March 2026.
This transaction represents one of Abbott’s most substantial acquisitions and signals a strategic expansion into oncology diagnostics. Revenue generated by this division helped propel the Q1 revenue outperformance.
Medical Device Segment Maintains Momentum
Abbott’s medical device division continues as its primary revenue source. The segment posted another strong quarter in Q1, providing crucial support for the overall revenue beat.
The organization has relied heavily on its device portfolio as a fundamental growth engine for multiple consecutive quarters. This pattern persisted throughout the initial three months of 2026.
Forward Guidance Falls Marginally Short of Projections
For the second quarter of 2026, Abbott projected EPS between $1.25 and $1.31. Analyst consensus stood at $1.32, positioning Abbott’s midpoint guidance slightly beneath Wall Street’s expectation.
For fiscal year 2026, Abbott anticipates EPS ranging from $5.38 to $5.58. The analyst consensus of $5.47 falls comfortably within this projected range.
Abbott experienced zero positive EPS estimate revisions alongside 18 downward revisions over the past 90 days. This represents a downgrade from the previous quarter’s “great performance” financial health assessment — InvestingPro currently assigns Abbott a “good performance” financial health rating.
The revenue outperformance provides confidence, despite guidance ranges that didn’t completely align with analyst expectations. Abbott’s Q1 top-line results represented the strongest component of this quarterly report.
The full-year EPS consensus of $5.47 remains within Abbott’s projected band of $5.38 to $5.58, allowing opportunity for the company to achieve or surpass this benchmark as 2026 progresses.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
